ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Hematologic Cancer Targets

Is Cytomegalovirus Linked to Childhood Leukemia Risk?

These findings suggest the possibility that ALL could be prevented with antiviral interventions or vaccination. Image © Jarun Ontakrai/Shutterstock.com 

Hematologic Cancer Targets

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

Patients with mucosa-associated lymphoid tissue (MALT) lymphoma had improved event-free survival when treated with chlorambucil plus rituximab compared with either therapy alone.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Researchers at the Mayo Clinic are reporting that they have identified a new therapy that shrinks tumors in patients with multiple myeloma.

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

Genetic profiling combined with clinical factors may help guide clinicians on how to better manage patients with myelodysplastic syndrome.

Pages

Subscribe to Hematologic Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.